Recent Advances in Vaccines and Drugs Against the Ebola Virus.
- Author:
Xiang ZHU
;
Chenguang YAO
;
Yanhong WEI
;
Zheng KOU
;
Kanghong HU
- Publication Type:Journal Article
- MeSH:
Animals;
Antiviral Agents;
administration & dosage;
Ebola Vaccines;
administration & dosage;
genetics;
immunology;
Ebolavirus;
drug effects;
genetics;
immunology;
physiology;
Hemorrhagic Fever, Ebola;
drug therapy;
prevention & control;
virology;
Humans
- From:
Chinese Journal of Virology
2015;31(3):287-292
- CountryChina
- Language:Chinese
-
Abstract:
The Ebola virus belongs to the Filovirus family, which causes Ebola hemorrhagic fever (mortality, 25%-90%). An outbreak of infection by the Ebola virus is sweeping across West Africa, leading to high mortality and worldwide panic. The Ebola virus has caused a serious threat to public health, so intensive scientific studies have been carried out. Several vaccines (e.g., rVSV-ZEBOV, ChAd3-ZEBOV) have been put into clinical trials and antiviral drugs (e.g., TKM-Ebola, ZMAPP) have been administered in the emergency setting to patients infected by the Ebola virus. Here, recent advances in vaccines and drugs against the Ebola virus are reviewed.
